Optimal Monitoring (optimal + monitoring)

Distribution by Scientific Domains


Selected Abstracts


Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit,

JOURNAL OF MEDICAL VIROLOGY, Issue 8 2010
Marifina Chilet
Abstract Cytomegalovirus (CMV) reactivation occurs frequently in critically ill patients. The natural course of CMV infection and the interaction between CMV and the adaptive immune system in this setting remain poorly defined. Fifty-three CMV-seropositive patients in a surgical and trauma intensive care unit were included in this study. The CMV DNA load in tracheal aspirates (TA) and plasma (PL) was monitored by qPCR. CMV-specific T-cell immunity was assessed by intracellular cytokine staining. Plasma TNF-, levels were determined by ELISA. CMV reactivation occurred in 39.7% of patients (23% had CMV DNA detected only in TA). The analysis of TA allowed an earlier diagnosis in 28% of patients. Clearance of CMV DNAemia preceded that of CMV DNA in TA in some episodes. Peak CMV DNA levels were significantly higher in TA than in PL (P,=,0.02). CMV reactivation developed in the presence of CMV-specific T cells. Termination of CMV reactivation was associated with an expansion of functional CMV-specific T cells. Plasma levels of TNF-, did not allow for the prediction of the occurrence of CMV reactivation. CMV-specific T-cell immunity is preserved in most critically ill patients experiencing CMV reactivation. Analysis of respiratory specimens is imperative for an optimal monitoring of CMV reactivation in this setting. J. Med. Virol. 82:1384,1391, 2010. © 2010 Wiley-Liss, Inc. [source]


Effective securement of BIS sensors for optimal monitoring

ACTA ANAESTHESIOLOGICA SCANDINAVICA, Issue 5 2006
S. D. Adhikary
No abstract is available for this article. [source]


MxA protein assay for optimal monitoring of IFN-, bioactivity in the treatment of MS patients

ACTA NEUROLOGICA SCANDINAVICA, Issue 1 2008
A.-M. Vallittu
Objectives,,, Myxovirus resistance protein A (MxA) can be used as a marker of the bioactivity of interferon-beta (IFN-,) therapy. Two to forty per cent of IFN-,-treated multiple sclerosis (MS) patients develop IFN-,-neutralizing antibodies (NAb) with subsequent attenuation of MxA protein induction. The aim of this study was to set up a simple MxA enzyme immunoassay (EIA) for the measurement of MxA protein and to evaluate the EIA test by comparing the results with flow cytometric analysis and the measurement of NAb. Methods,,, total of 51 IFN-,-treated relapsing,remitting MS (RRMS) patients were tested for MxA protein expression by using both MxA EIA assay and flow cytometric analysis. Thirteen patients were confirmed to be NAb-positive. Results,,, The correlation between EIA and flow cytometric analysis was significant with a wider range of measured levels in the EIA. Patients with NAb had low MxA levels, but in some patients, remaining MxA induction could be detected despite NAb. Conclusions,,, The MxA EIA assay seems to be a practical method for large-scale analysis of the bioactivity of IFN-, treatment. [source]


Optimised monitoring of inflammation suppressive therapy (IST) in uveitis

ACTA OPHTHALMOLOGICA, Issue 2009
CP HERBORT
Purpose The array of inflammation suppressive therapies (IST) has increased trumendously in the last two decades including the availability of biological molecules with potent immunomodulatary activities as well as new immunosuppressive agents. In parallel measuring methods for intraocular inflammation have become available allowing much more acurate monitoring of the evolution of inflammation and its response to therapy. In addition to the traditionally used fluorescein angiography (FA), laser flare photometrry (LFP), indocyanine green angiography ICGA) and optical coherence tomography (OCT) are among the new investigational methods that have become available, each of them allowing us to establish inflammatory activity with increased precision and to explore compartments previously poorly accessible. Methods The advantages of each method will be put forward. Illustrative cases will be taken as examples to show the degree of precision obtained by combining the different methods presently at our disposal for the follow-up and monitoring of inflammation suppressive treatment. Results These cases will show that the presently available tools for optimal monitoring of intraocular inflammation allow the clinician to be better aware of the level of inflammatory activity and to better adapt his treatment. Conclusion Not only he availability of potent new therapies but also the possibility to follow more precisely intraocular inflammation with new precise devices has certainly changed the outcome of uveitis cases in recent years. [source]